MSD makes its obesity move with Hansoh deal
MSD has been rumoured to be considering a takeover of Viking Therapeutics in order to get a horse in the obesity therapy race but chose instead to back a runner from China's Hansh Pharma.
Merck moves into obesity with deal for Hansoh’s GLP-1 pill
News of Merck’s licensing of Hansoh’s preclinical medicine pressured shares in Viking and other obesity drug developers seen as likely buyout targets.
Merck Joins Obesity Pill Race With Up to $2B Hansoh Deal
The Hansoh deal will let Merck compete in the crowded oral GLP-1 space alongside fellow pharma giants Eli Lilly, Novo Nordisk and Roche.
Merck signs deal worth up to $2 billion with China's Hansoh for oral obesity drug
Merck on Wednesday signed a deal worth up to $2 billion with Hansoh Pharma to develop and sell the Chinese biotech's experimental oral obesity drug that works similar to the popular weight-loss treatments Wegovy and Zepbound.
Merck snags Chinese obesity drug in nearly US$2 billion deal
MERCK snagged a potential drug in the burgeoning market for obesity medications in a deal worth as much as US$2 billion. Read more at The Business Times.
Merck to develop weight loss pill from Chinese drugmaker in up to $2 billion licensing deal
Under the terms of the deal, Merck will gain the exclusive global license to develop, manufacture and commercialize Hansoh Pharma's HS-10535, an experimental oral drug that targets a gut hormone called GLP-1. Novo Nordisk's popular weight loss drug Wegovy ...
Merck reaches weight-loss drug deal worth up to $2 billion with China-based Hansoh
Merck announced a weight loss drug deal Wednesday with China-based Hansoh worth up to $2 billion for the pill code-named HS-10535. It includes a $112 million licensing rights payment for global sales outside China.
Merck signs up to $2 billion obesity drug deal with Chinese biotech Hansoh
U.S. drugmaker Merck on Wednesday signed a deal worth up to $2 billion with Hansoh Pharmaceuticals to develop and commercialize the Chinese biotech's experimental obesity drug. Under the deal, Merck will pay $112 million upfront and Hansoh will be eligible to receive up to $1.
Merck, Hansoh Pharma in Obesity Pill License Potentially Worth More Than $2 Billion
Merck & Co. is licensing a potential oral obesity drug from Hansoh Pharma in a deal potentially worth more than $2 billion to the Chinese biopharmaceutical company. Merck on Wednesday said it will make an upfront payment of $112 million to Hansoh in exchange for an exclusive global license to HS-10535,
Merck Strikes Deal With China's Hansoh Pharma to Develop Weight Loss Drug
Merck (MRK) secured exclusive rights to develop and sell an oral weight loss drug under a license deal with Hansoh Pharma that could fetch the Chinese biopharmaceutical company up to $2 billion. Merck agreed to pay $112 million up front to Hansoh Pharma,
FierceBiotech23h
Merck & Co. boosts GLP-1 portfolio by paying $112M upfront for Hansoh's preclinical drug
Merck & Co. has added a second GLP-1 candidate to its pipeline, paying China’s Hansoh Pharma $112 million upfront for a ...
Merck and Hansoh Pharma sign exclusive global license agreement for HS-10535
Merck (MRK) and Hansoh Pharma, a Chinese biopharmaceutical company, announced that they have entered into an exclusive global license agreement ...
What's Going On With Merck Shares Wednesday?
Merck & Company Inc (NYSE:MRK) shares are trading higher. The company on Wednesday announced a GLP-1 agreement with Chinese ...